PULSE BIOSCIENCES, INC. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 32/100
What the filing says
On September 15, 2026, Pulse Biosciences entered into an Equity Distribution Agreement with Mizuho Securities USA LLC to sell up to $85 million of common stock at-the-market through Mizuho acting as sales agent. The Company will pay Mizuho up to 3.0% commission on gross sales proceeds. Shares will be offered pursuant to an effective Form S-3 registration statement (File No. 333-293596) filed February 19, 2026 and declared effective February 27, 2026.
Why this rating
At-the-market offering worth 32% of company's $266.2M market cap—material financing flexibility but not yet executed; standard ATM boilerplate; dilution risk to shareholders contingent on actual sales.
Extracted items
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.